Gaviscon Double Action Mint as PPI add-on therapy in GORD patients

• Research type

  Research Study

• Full title

  A multicentre, randomised, double-blind, two arm, parallel group, pilot study to assess the effect of Gaviscon® Double Action Mint as add-on therapy in GORD patients with inadequate response to once daily proton pump inhibitor treatment.

• IRAS ID

  119590

• Contact name

  Alan G Wade

• Sponsor organisation

  Reckitt Benckiser (UK)Ltd

• Eudract number

  2012-004470-25

• Research summary

  The study will evaluate Gaviscon© Double Action Mint and matched placebo liquid as add-on treatments in GORD patients with persistent symptoms of Gastro-Oesophageal Reflux (GOR), despite taking a PPI once daily for at least 4 weeks. Symptoms of GORD will be assessed using patient self-assessment questionnaires.

• REC name

  Scotland A REC

• REC reference

  12/SS/0232

• Date of REC Opinion

  8 Jan 2013

• REC opinion

  Further Information Favourable Opinion